Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-04-14
2008-12-16
Foley, Shanon A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S190100, C435S069100
Reexamination Certificate
active
07465457
ABSTRACT:
The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide.
REFERENCES:
CRC Handbook of Chemistry and Physics, 78th edition, CRC Press, 1997, p. 2-53.
Cai S & Singh B, “A correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution,” Biochemistry 40:4693-4702 (2001).
Dineen S, et al., “Neurotoxin gene clusters inClostridium botulinumtype A strains: sequence comparison and evolutionary implications,” Curr. Microbiol. 46:345-352 (2003).
Kadkhodayan S, et al., “Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A,” Protein Expr. Purif. 19:125-130 (2000).
Kurazono H, et al., “Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A,” J. Biol. Chem. 267:14721-14729 (1992).
LaPenotiere H, et al., “Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen,” Toxicon 33:1383-1386 (1999).
Li L & Singh B, “High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain,” Protein Expr. Purif. 17:339-344 (1999).
Li Y, et al., “A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain,” Biochemistry 33:7014-7020 (1994).
Rossetto O, et al., “Active-site mutagenesis of tetanus neurotoxin implicates TYR-375 and GLU-271 in metalloproteolytic activity,” Toxicon 39:1151-1159 (2001).
Zhou L, et al.; “Expression and purification of the light chain of botulinum neurotoxin A: a single mutatio abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain,” Biochemisty 34:15175-15181 (1995).
Baldwin Michael
Barbieri Joseph T.
Bradshaw Marite
Johnson Eric A.
Foley Shanon A.
Gangle Brian J
Quarles & Brady LLP
The MCW Research Foundation, Incorporated
Wisconsin Alumni Research Foundation
LandOfFree
Method for preparing botulinum neurotoxin type A light chain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing botulinum neurotoxin type A light chain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing botulinum neurotoxin type A light chain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039038